Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)

https://www.faronpharmaceuticals.com

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. *

	Start	2015-05-20 existent
	Industry	Traumakine®
	Industry 2	Clevegen
	Person	Jalkanen, Markku (Faron Pharmaceuticals 201505 CEO)

	Region	Turku
	Country	Finland
	Street	6 B Tykistökatu BioCity
	City	20520 Turku
	Tel	+358-2-469-5151
		Address record changed: 2023-03-29

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	185,000 (income, total, consolidated (2019) 2019-12-31)
	Profit	13,262,000 (2019-12-31)
	Cash	7,059,000 (2019-12-31)

		* Document for »About Section«: Faron Pharmaceuticals Oy. (1/4/21). "Press Release: Faron to Present at H.C. Wainwright BioConnect". Turku.

		Record changed: 2024-02-12